Increased serum S100B levels in chronic schizophrenic patients on long-term clozapine or typical antipsychotics

Neuroscience Letters

Volumn 462, Issue 2, 2009, Pages 113-117

  Qi, Ling Yan ^a   Xiu, Mei Hong ^a   Chen, Da Chun ^a   Wang, Fan ^a   Kosten, Therese A ^b   Kosten, Thomas R ^b   Zhang, Xiang Yang ^a,b  

^a BEIJING HUILONGGUAN HOSPITAL   (China)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Antipsychotics; Neurotrophin; Psychopathology; S100B; Schizophrenia; Serum

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; PERPHENAZINE; PROTEIN S100B;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; CLOZAPINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; NERVE GROWTH FACTORS; S100 PROTEINS; SCHIZOPHRENIA;

EID: 67650973416     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2009.06.019     Document Type: Article

References (34)

1. Araque A., Sanzgiri R.P., Parpura V., and Haydon P.G. Astrocyte-induced modulation of synaptic transmission. Can. J. Physiol. Pharmacol. 77 (1999) 699-706
2. Beaudeux J., Dequen L., and Foglietti M. Pathophysiologic aspects of S-100beta protein: a new biological marker of brain pathology. Ann. Biol. Clin. (Paris) 57 (1999) 261-272
3. Buckley P.F., Mahadik S., Pillai A., and Terry Jr. A. Neurotrophins and schizophrenia. Schizophr. Res. 94 (2007) 1-11
4. Cotter D.R., Pariante C.M., and Everall I.P. Glial cell abnormalities in major psychiatric disorders: the evidence and implications. Brain Res. Bull. 55 (2001) 585-595
5. Falkai P., Honer W.G., David S., Bogerts B., Majtenyi C., and Bayer T.A. No evidence for astrogliosis in brains of schizophrenic patients. A post-mortem study. Neuropathol. Appl. Neurobiol. 25 (1999) 48-53
6. Fano G., Biocca S., Fulle S., Mariggio M.A., Belia S., and Calissano P. The S-100: a protein family in search of a function. Prog. Neurobiol. 46 (1995) 71-82
7. Gattaz W.F., Lara D.R., Elkis H., Portela L.V., Goncalves C.A., Tort A.B., Henna J., and Souza D.O. Decreased S100-beta protein in schizophrenia: preliminary evidence. Schizophr. Res. 43 (2000) 91-95
8. Grillo R.W., Ottoni G.L., Leke R., Souza D.O., Portela L.V., and Lara D.R. Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. J. Psychiatr. Res. 41 (2007) 31-35
9. Hu J., Ferreira A., and Van Eldik L.J. S100beta induces neuronal cell death through nitric oxide release from astrocytes. J. Neurochem. 69 (1997) 2294-2301
10. Kirch D.G., Alexander R.C., Suddath R.L., Papadopoulos N.M., Kaufmann C.A., Daniel D.G., and Wyatt R.J. Blood-CSF barrier permeability and central nervous system immunoglobulin G in schizophrenia. J. Neural. Transm. Gen. Sect. 89 (1992) 219-232
11. Lara D.R., Gama C.S., Belmonte-de-Abreu P., Portela L.V., Goncalves C.A., Fonseca M., Hauck S., and Souza D.O. Increased serum S100B protein in schizophrenia: a study in medication-free patients. J. Psychiatr. Res. 35 (2001) 11-14
12. Ling S.H., Tang Y.L., Jiang F., Wiste A., Guo S.S., Weng Y.Z., and Yang T.S. Plasma S-100B protein in Chinese patients with schizophrenia: comparison with healthy controls and effect of antipsychotics treatment. J. Psychiatr. Res. 41 (2007) 36-42
13. Marenco S., and Weinberger D.R. The neurodevelopmental hypothesis of schizophrenia: following a trail of evidence from cradle to grave. Dev. Psychopathol. 12 (2000) 501-527
14. Missler U., and Wiesmann M. Measurement of S-100 protein in human blood and cerebrospinal fluid: analytical method and preliminary clinical results. Eur. J. Clin. Chem. Clin. Biochem. 33 (1995) 743-748
15. Nygaard O., Langbakk B., and Romner B. Age- and sex-related changes of S-100 protein concentrations in cerebrospinal fluid and serum in patients with no previous history of neurological disorder. Clin. Chem. 43 (1997) 541-543
16. Parikh V., Evans D.R., Khan M.M., and Mahadik S.P. Nerve growth factor in never-medicated first-episode psychotic and medicated chronic schizophrenic patients: possible implications for treatment outcome. Schizophr. Res. 60 (2003) 117-123
17. Pedersen A., Diedrich M., Kaestner F., Koelkebeck K., Ohrmann P., Ponath G., Kipp F., Abel S., Siegmund A., Suslow T., von Eiff C., Arolt V., and Rothermundt M. Memory impairment correlates with increased S100B serum concentrations in patients with chronic schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 32 (2008) 1789-1792
18. Pirildar S., Gonul A.S., Taneli F., and Akdeniz F. Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 28 (2004) 709-713
19. Rothermundt M., Falkai P., Ponath G., Abel S., Burkle H., Diedrich M., Hetzel G., Peters M., Siegmund A., Pedersen A., Maier W., Schramm J., Suslow T., Ohrmann P., and Arolt V. Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF. Mol. Psychiatry 9 (2004) 897-899
20. Rothermundt M., Missler U., Arolt V., Peters M., Leadbeater J., Wiesmann M., Rudolf S., Wandinger K.P., and Kirchner H. Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology. Mol. Psychiatry 6 (2001) 445-449
21. Rothermundt M., Ohrmann P., Abel S., Siegmund A., Pedersen A., Ponath G., Suslow T., Peters M., Kaestner F., Heindel W., Arolt V., and Pfleiderer B. Glial cell activation in a subgroup of patients with schizophrenia indicated by increased S100B serum concentrations and elevated myo-inositol. Prog. Neuropsychopharmacol. Biol. Psychiatry 31 (2007) 361-364
22. Rothermundt M., Ponath G., and Arolt V. S100B in schizophrenic psychosis. Int. Rev. Neurobiol. 59 (2004) 445-470
23. Rothermundt M., Ponath G., Glaser T., Hetzel G., and Arolt V. S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia. Neuropsychopharmacology 29 (2004) 1004-1011
24. Sarandol A., Kirli S., Akkaya C., Altin A., Demirci M., and Sarandol E. Oxidative-antioxidative systems and their relation with serum S100 B levels in patients with schizophrenia: effects of short term antipsychotic treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 31 (2007) 1164-1169
25. Schmitt A., Bertsch T., Henning U., Tost H., Klimke A., Henn F.A., and Falkai P. Increased serum S100B in elderly, chronic schizophrenic patients: negative correlation with deficit symptoms. Schizophr. Res. 80 (2005) 305-313
26. Schmitt A., Steyskal C., Bernstein H.G., Schneider-Axmann T., Parlapani E., Schaeffer E.L., Gattaz W.F., Bogerts B., Schmitz C., and Falkai P. Stereologic investigation of the posterior part of the hippocampus in schizophrenia. Acta Neuropathol. 117 (2009) 395-407
27. Schroeter M.L., Abdul-Khaliq H., Fruhauf S., Hohne R., Schick G., Diefenbacher A., and Blasig I.E. Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia. Schizophr. Res. 62 (2003) 231-236
28. Schroeter M.L., Mertsch K., Giese H., Muller S., Sporbert A., Hickel B., and Blasig I.E. Astrocytes enhance radical defence in capillary endothelial cells constituting the blood-brain barrier. FEBS Lett. 449 (1999) 241-244
29. Steiner J., Bernstein H.G., Bielau H., Berndt A., Brisch R., Mawrin C., Keilhoff G., and Bogerts B. Evidence for a wide extra-astrocytic distribution of S100B in human brain. BMC Neurosci. 8 (2007) 2
30. Steiner J., Bernstein H.G., Bogerts B., Gos T., Richter-Landsberg C., Wunderlich M.T., and Keilhoff G. S100B is expressed in, and released from, OLN-93 oligodendrocytes: influence of serum and glucose deprivation. Neuroscience 154 (2008) 496-503
31. Steiner J., Walter M., Wunderlich M.T., Bernstein H.G., Panteli B., Brauner M., Jacobs R., Gos T., Rothermundt M., and Bogerts B. A new pathophysiological aspect of S100B in schizophrenia: potential regulation of S100B by its scavenger soluble RAGE. Biol. Psychiatry (2008)
32. van Beveren N.J., van der Spelt J.J., de Haan L., and Fekkes D. Schizophrenia-associated neural growth factors in peripheral blood. A review. Eur. Neuropsychopharmacol. 16 (2006) 469-480
33. Wiesmann M., Wandinger K.P., Missler U., Eckhoff D., Rothermundt M., Arolt V., and Kirchner H. Elevated plasma levels of S-100b protein in schizophrenic patients. Biol. Psychiatry 45 (1999) 1508-1511
34. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry 64 (2003) 663-667